PRESSEERKLÄRUNGEN

GESUNDHEITSPOLITIK

- ein Projekt des Info-Netzwerk Medizin 2000 -

www.gesundheitspolitik.presseerklaerungen.de

Bildnachweis: Fotolia   aktualisiert: 09.12.19, Uhrzeit: 21.57





Presseerklärungen

im Info-Netzwerk
MEDIZIN 2000


28.9.19


















Themenwebsites

im Info-Netzwerk.
Medizin 2000
18.10.2019








PRESS RELEASE

HIGH DRUG COSTS DESPITE PUBLIC R&D FUNDING IN THE MILLIONS



Ludwig Boltzmann Institute for Health Technology Assessment (Vienna, Austria) identifies public funding for the development of high-priced drugs. New investigational search strategy aims at contributing to greater transparency. Three pilot studies were conducted, more will follow.


Vienna, Austria, 26 September 2019 - EUR 165 million in public and private R&D grants for the discovery and development of a drug that generates millions in revenue per patient (!) for a pharmaceutical company. Numerous public research grants were also identified for the development of two other high-priced drugs. This was possible thanks to a search strategy developed by LBI-HTA, intending to create more transparency about the societal value of public investments in the health care system and therefore supports the demand for a „public return on public investment“.


Newly developed drugs are increasingly becoming extremely expensive. This poses new challenges for healthcare systems. The OECD has been addressing this problem for some time, as it restricts “access to medicines”. In May of this year, the World Health Organization WHO adopted a resolution calling for greater transparency in the pricing of medicines. The Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) in Vienna has now developed methods precisely for this purpose. They allow the identification of public and philanthropic funds that contribute to the discovery and development of an approved drug.




LOTS OF MONEY. POOR TRANSPARENCY.


" For the time being, we have piloted our method on three drugs and have been able to prove that all three drugs have received grants to the value of millions of Euros in several digits" says Priv. Doz. Dr. phil. Claudia Wild, head of the LBI-HTA, representing the quintessence of the study. "These funds were provided at different stages of discovery and development of the drug by public or philanthropic sources. All three drugs are sold by pharmaceutical companies. "The three compounds studied are: Nusinersen (against spinal cord atrophy, a rare neuromuscular disorder), Cerliponase alfa (to treat a hereditary disease in children that leads to progressive brain damage) and Burosumab (against a genetic disease in children that can lead to weak bones and lifelong physical disabilities). All three drugs are therapies against rare diseases in children.

"High R&D costs are often cited by manufacturers as a reason for the high costs of their drugs, therefore transparency about public research funding contributions should be very important. However, this is precisely not the case," explains Dr. Wild. In fact, basic research - publicly and philanthropically financed - often provides the discovery or brilliant idea that later finds application in a drug - and at the same time is associated with a high degree of uncertainty regarding results and high expenditure of resources.


THE TRANSPARENCY PUZZLE


The LBI-HTA sought to shed light on the question of public funding and contribute to creating transparency around this issue. . "In fact, we had to develop our own search methodology in order to assemble puzzle pieces of information from numerous public sources, which in the end resulted in enormous sums of funding," stresses Dr. Wild. The search strategy is structured in three stages:

Stage 1: All generic and molecular names and terms of the medicinal product or its active ingredient are identified. This is done for the entire R&D process and in several relevant databases (e.g. DrugBank, ChEMBL, Therapeutic Target Database).

Stage 2: The drug's development path up to approval is determined using further trial and patent databases (e.g. Orphanet, WHO international trial register, US Clinical Trials.Gov, EU clinical trials registry, FDA orange book, Espacenet, Health Canada Patent, PubMed and many more).

Stage 3: A systematic search for research grants based on the identified names and development pathways in other databases (e.g. NIH-RePORTER, CORDIS, IMI, EDCTP and various philanthropic data sources) is finally conducted.

However, even with this structured method and despite a high level of commitment, the picture of funding in the development of the three drugs remained incomplete. For instance, although more than 20 publicly or philanthropically financed projects were found for the discovery and development of Cerliponase alfa, the exact funding amounts were often not available. Nevertheless, we could estimate that EUR 31 million in funding had been allocated to projects that directly served product development alone. The picture was similar with Burosumab: numerous public and some philanthropic projects supported the discovery and development of the drug, but only funding amounts totalling EUR 26 million could be quantified.

There were several difficulties in the analysis. The biggest challenge was in distinguishing between basic research (which can aid an entire product class as well as knowledge about the disease itself) and research for the development of a specific product.

Despite all the difficulties, the method developed by the LBI-HTA enables a significant increase in transparency about the use of public and philanthropic funds in the discovery of new active substances and the drug development based on them. Thus, the project makes a significant contribution to the current and international discussion on "Return on Investment of Public Investment".


Reference:
Schmidt L., Wild C. Public & philanthropic financial contribution to the development of new drugs.
LBI-HTA Project Report No.: 120; Year 2019. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

 http://eprints.hta.lbg.ac.at/1214/


PR&D - Public Relations für Forschung & Bildung

Mariannengasse 8
1090 Vienna, Austria

http://www.prd.at




 






> zum Seitenanfang







Wenn Sie den Mauszeiger über eine Anzeige bewegen, dann können Sie damit den Bilddwechsel beliebig lange unterbrechen um den Text in Ruhe lesen zu können. Ein einfacher Mausklick ruft dann die gewünschte Website auf.


WERBUNG INFO-NETZWERK MEDIZIN 2000

Hier können  Kooperationspartner die Mitglieder ihrer  jeweiligen Zielgruppen über ihr Unternehmen, ihre besonderen Kompetenzgebiete, sowie die von ihnen engebotenen Produkte und  Dienstleistungen werbend informieren.  

25.09.2019
 


 
Bio-Nutzhanf-Produkte
Das österreichische Unternehmen
Deep Nature Project
stellt Produkte
her, die den an Alternativen zu herkömmlichen Produkten interessierten Verbrauchern  die Chance bieten, die hochwertigen naturbelassenen   Inhaltsstoffe von Bio-Hanf zu nutzen. Die faserreichen Hanf-Pflanzen werden von den
kooperierenden Bio-Landwirten
ausschließlich aus EU-zugelassenem

Bio-Nutzhanf gezogen.
Hier geht es zum online Shop.


 

Ohne Schmerzen leben

Die Hochton-Frequenz-Therapie ist eine sehr effektive, schon viele Jahre bekannte elektrotherapeutische Behandlung. WeWoThom® Premium ist eine spezielle Form der Hochton-Frequenz-Therapie zur Selbstanwendung durch die betroffenen Patienten. Das Verfahren arbeitet mit elektromagnetischen Frequenzen aus dem Bereich zwischen ca. 4.000 und 12.000 Hertz und wird sehr erfolgreich angewandt bei Direktbestellung bei WeWoThom hier
Sanorell Pharma empfiehlt eine Serie von Gesundheitsratgebern - beispielsweise diese:



Der Sanorell Vital-Test hat ergeben, dass 47% der Frauen und 45% der Männer nicht ausreichend mit Vitaminen und Spurenelementen versorgt sind.
Der Vital-Test zeigt, ob es sinnvoll ist, einen entdeckten Mangel durch passende,  in jeder Apotheke rezeptfrei zu kaufende Nahrungsergänzungsmittel auszugleichen. Über die Versandapotheke Fixmedika können Sie sich die Sanorell Arzneimittel der Vital Plus-Kombination kostengünstig  zusenden lassen.
Ärzte und viele Patienten interessieren sich zunehmend  für die  vielfältigen, nahezu nebenwirkungsfreien  Möglichkeiten,  mit Hilfe von Atemgas-Analysen  bisher oft übersehene  Gesundheitsstörungen zu erkennen und die Therapieerfolge zu managen. Einige Unternehmen bieten Ärzten und Patienten in Deutschland  Atemgas-Analyse-Geräte an.
Zur  Produkt-Palette gehören der zu selten angewandte FeNO-Atemtest, der sich für die Asthma-Diagnose und die Therapiekontrolle eignet, der H2 Atemtest  zur Diagnose einer Laktose-Unverträglichkeit und der
CO-Atemtest
als Hilfe bei der   Rauchenentwöhnung .
Linkliste Medizin 2000



Wichtige Themen-Websites im Info-Netzwerk Medizin 2000 
aktualisiert 20.10.19


 
 |  Ärzte Spezialisten | Arthrose Therapie | Aspirin-Therapie | Asthma Therapie | Asthma Management  | Asthma Diagnose | Atemgas-Analysen |  Augenheilkunde |
 
 | Bienengift Allergie | Biologischer Bypass  | Bio-Nutzhanf-Produkte | Brustkrebs   | Burnout Syndrom | COPD | Deutsche Ärzte |  Deutsche Fachärzte | Diabetes | Depressionen |  
| Erektile Dysfunktion |   Endoprothese | Erkältungen | Evidence based Medicine | FeNO-Atemtest Frauenheilkunde | Frischzellen-Therapie German Hospitals | German Leading Hospitals |
| PE Gesundheitspolitik | Glaukom | Gräser Impf Tablette | Grippe  |  Hausarzt | Hausstaubmilben Allergie | Herpes zoster  |Herzkrankheiten | Herzinfarkt Prophylaxe |
| Herzinfarkt TherapieHerzinsuffizienz  |  Herzrhythmusstoerungen |   Heuschnupfen | Highlights Forschung | Homöopathie | Homöopunktur |
 
 
 
 
 
 
| Rückenschmerzen | Report Medizin | Rheuma |  Schlaganfall | Science Podcast  | Scheidenpilz | Schmerztherapie | Schwerhörigkeit | Selbstheilung |  Spezifische Immuntherapie |
 
 | Vaterschaftstest Video Podcast | Vital-Test | Vitamine und Spurenelemente | Versandapotheken | Wespengiftallergie |   Zuckerkrankheit |
  | Stichwortsuche Medizin 2000   Impressum |